Order Article Reprints

Wang S, Malebari AM, Greene TF, Kandwal S, Fayne D, Nathwani SM, Zisterer DM, Twamley B, O’Boyle NM, Meegan MJ. Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000. Pharmaceuticals. 2025; 18(8):1218. https://doi.org/10.3390/ph18081218

Wang, Shu, Azizah M. Malebari, Thomas F. Greene, Shubhangi Kandwal, Darren Fayne, Seema M. Nathwani, Daniela M. Zisterer, Brendan Twamley, Niamh M. O’Boyle, and Mary J. Meegan. 2025. "Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000" Pharmaceuticals 18, no. 8: 1218. https://doi.org/10.3390/ph18081218

Wang, S., Malebari, A. M., Greene, T. F., Kandwal, S., Fayne, D., Nathwani, S. M., Zisterer, D. M., Twamley, B., O’Boyle, N. M., & Meegan, M. J. (2025). Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000. Pharmaceuticals, 18(8), 1218. https://doi.org/10.3390/ph18081218